AbbVie (NYSE: ABBV) has agreed to acquire Apogee Therapeutics (Nasdaq: APGE) in an all-cash transaction valued at approximately USD 10.9 billion, adding a late-stage pipeline of half-life extended antibodies targeting inflammatory and immunological diseases. AbbVie is paying USD 135.11 per share to acquire Massachusetts-based Apogee's clinical-stage portfolio spanning atopic dermatitis, asthma, and related inflammatory indications, extending its immunology franchise beyond its current anchors in risankizumab (Skyrizi) and upadacitinib (Rinvoq).
The agreement is definitive with approval from both boards, with AbbVie paying all cash and no milestone conditions attached. Closure is expected in Q3 2026, subject to Apogee shareholder approval and customary regulatory clearances. Fairmount Funds Management and Venrock Associates have entered into voting agreements in support of the deal.
The primary driver of the acquisition is zumilokibart (APG777), a subcutaneous, half-life extended monoclonal antibody targeting IL-13, a cytokine central to type 2 inflammation in atopic dermatitis and asthma. Zumilokibart's engineering enables dosing intervals of every three or six months — compared with every two weeks for dupilumab (Dupixent, Sanofi) and tralokinumab (Adbry/Adtralza, Leo Pharma), its most direct competitors in the IL-13 and IL-4/IL-13 pathway space. In the Phase II APEX Part A trial, 52-week maintenance data demonstrated that 75% and 85% of Week 16 responders maintained EASI-75 on every-three-month and every-six-month dosing, respectively, with deepening of responses observed across the full treated population. The Phase II APEX Part B dose-optimization cohort, which met all primary and secondary endpoints in May 2026, is expected to support Phase III initiation in moderate-to-severe atopic dermatitis in the second half of 2026.
While zumilokibart appears to be the primary value driver, AbbVie also gains APG273, a fixed-dose combination of zumilokibart and APG333, an anti-TSLP half-life extended antibody targeting the upstream inflammatory trigger in asthma and COPD. Phase I data for APG333 demonstrated suppression of type 2 inflammatory markers for up to six months after a single dose, supporting quarterly or twice-yearly co-administration. The TSLP-targeting space has attracted significant competitive interest, with independent programs advancing toward later-stage development, illustrating the broader industry validation of long-acting biologics in respiratory type 2 inflammation.
For AbbVie, the acquisition addresses a specific pipeline gap. As flagged during its Q1 2026 earnings call, the company has been executing a structured immunology M&A strategy — including the USD 2.1 billion acquisition of Capstan Therapeutics for an in vivo anti-CD19 CAR-T platform, and the earlier acquisition of Nimble Therapeutics for oral peptide IL-23R inhibitors — to build a post-Humira pipeline with durable revenue potential. The Apogee deal adds two near-Phase III assets in significant markets: atopic dermatitis, where AbbVie already markets Rinvoq, and asthma, where it currently has no approved biologic. The company's previous option-to-acquire Kestrel Therapeutics for up to USD 1.45 billion illustrates the range of deal structures AbbVie has deployed; the Apogee transaction is a straightforward full acquisition, reflecting the advanced clinical stage and potentially de-risked profile of the assets.